Article
Oncology
Lin Shi, Jinying Lu, Da Zhong, Meijuan Song, Jian Liu, Wenhua You, Wen-Hui Li, Lin Lin, Dongyan Shi, Yun Chen
Summary: Mucosal-associated invariant T (MAIT) cells in non-small cell lung cancer (NSCLC) patients exhibit an exhausted tumor-promoting phenotype and the subset of circulating MAIT cells can predict the response to anti-PD-1 immunotherapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Khalid Jazieh, Mohammadhadi Khorrami, Anas Saad, Mohamed Gad, Amit Gupta, Pradnya Patil, Vidya Sankar Viswanathan, Prabhakar Rajiah, Charles J. Nock, Michael Gilkey, Pingfu Fu, Nathan A. Pennell, Anant Madabhushi
Summary: Radiomic patterns extracted from CT images of patients with unresectable stage III NSCLC were found to be prognostic of progression-free survival (PFS) and overall survival (OS) outcomes following chemoradiotherapy (CRT) with durvalumab immunotherapy (IO) and CRT alone.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Yanhong Liu, Lan Gao, Yanru Fan, Rufei Ma, Yunxia An, Guanghui Chen, Yan Xie
Summary: Potential protein biomarkers and mechanism of venous thromboembolism (VTE) in non-small cell lung cancer (NSCLC) patients were identified through proteomics research. A total of 280 differentially expressed proteins were found, and 5 proteins (SAA1, S100A8, LBP, HP and LDHB) showed significant changes between VTE and non-VTE patients. These results suggest that these proteins may be used for diagnosing VTE in NSCLC patients.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Masayuki Sato, Yukihiro Umeda, Tetsuya Tsujikawa, Tetsuya Mori, Miwa Morikawa, Masaki Anzai, Yuko Waseda, Maiko Kadowaki, Yasushi Kiyono, Hidehiko Okazawa, Tamotsu Ishizuka
Summary: Changes in F-18-FLT PET parameters may serve as an early predictive biomarker for the response to anti-PD-1 therapy in NSCLC patients, but pseudoprogression should be noted in imaging at 2 weeks after treatment initiation.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Medical Laboratory Technology
Long Zou, Luolin Wang, Lei Guo, Weixun Zhou, Zhizhen Lai, Cheng Zhu, Xi Wu, Zhili Li, Aiming Yang
Summary: This study found that regions associated with early gastric cancer have different lipid distributions and enzyme expressions compared to paracancerous regions. Phosphatidylcholine (32:0) and phosphatidylcholine (34:3) in serum are potential biomarkers for discriminating between early gastric cancer patients and healthy controls.
CLINICA CHIMICA ACTA
(2022)
Review
Biochemistry & Molecular Biology
Lucile Pabst, Sebastien Lopes, Basil Bertrand, Quentin Creusot, Maria Kotovskaya, Erwan Pencreach, Michele Beau-Faller, Celine Mascaux
Summary: The therapeutic algorithm for lung cancer has been revolutionized by immune checkpoint inhibitors, but the response rate and adverse events remain a challenge. Predictive and prognostic biomarkers are needed to select patients who will respond to treatment. Currently, PD-L1 expression is the only validated biomarker, but its predictive value is imperfect. New molecular features, such as tumor mutational burden, have shown promise in predicting response to immunotherapy. This review summarizes the latest knowledge on predictive and prognostic biomarkers to advance precision immuno-oncology.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Immunology
Jeffrey R. Whiteaker, Rachel A. Lundeen, Lei Zhao, Regine M. Schoenherr, Aura Burian, Dongqing Huang, Ulianna Voytovich, Tao Wang, Jacob J. Kennedy, Richard G. Ivey, Chenwei Lin, Oscar D. Murillo, Travis D. Lorentzen, Mathangi Thiagarajan, Simona Colantonio, Tessa W. Caceres, Rhonda R. Roberts, Joseph G. Knotts, Joshua J. Reading, Jan A. Kaczmarczyk, Christopher W. Richardson, Sandra S. Garcia-Buntley, William Bocik, Stephen M. Hewitt, Karen E. Murray, Nhan Do, Mary Brophy, Stephen W. Wilz, Hongbo Yu, Samuel Ajjarapu, Emily Boja, Tara Hiltke, Henry Rodriguez, Amanda G. Paulovich
Summary: Immunotherapies have transformed cancer care but face challenges such as low response rates, toxicities, and incomplete understanding of tumor immunobiology. A multiplex panel of proteomic assays targeting tumor-related proteins in tissue and plasma has been developed, showing impressive performance metrics and potential for future research use.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Julie Lecuelle, Laure Favier, Clea Fraisse, Aurelie Lagrange, Coureche Kaderbhai, Romain Boidot, Sandy Chevrier, Philippe Joubert, Bertrand Routy, Caroline Truntzer, Francois Ghiringhelli
Summary: In patients with non-small cell lung cancer (NSCLC), high expression of endogenous retroviruses (ERVs) was associated with better treatment efficacy and immune response. This study found that high MER4 ERV expression was associated with improved progression-free survival (PFS) and overall survival (OS) in NSCLC patients receiving immune checkpoint inhibitors (ICI). Additionally, adding MER4 to existing transcriptomic signatures improved the predictive power for response to ICI.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Niklas Kluemper, Jonas Saal, Fiamma Berner, Christa Lichtensteiger, Nina Wyss, Annkristin Heine, Franz Georg Bauernfeind, Joerg Ellinger, Peter Brossart, Stefan Diem, Sabine Schmid, Markus Joerger, Martin Frueh, Manuel Ritter, Michael Hoelzel, Lukas Flatz, Tobias Bald
Summary: Early dynamics of C reactive protein (CRP) can serve as a predictive biomarker for response to anti-PD-1 immune checkpoint blockade (ICB) in non-small cell lung cancer (NSCLC). CRP flare-responders can predict ICB response and survival as early as 4 weeks after therapy initiation. Early CRP kinetics have no predictive value for chemoimmunotherapy or when steroids are administered concurrently.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Alex K. K. Bryant, Kamya Sankar, Garth W. W. Strohbehn, Lili Zhao, David Elliott, Angel Qin, Sarah Yentz, Nithya Ramnath, Michael D. D. Green
Summary: This study demonstrates that pre-treatment NLR is a prognostic factor in stage III NSCLC patients treated with adjuvant immunotherapy, and it may also serve as a predictive biomarker of immunotherapy benefit.
Article
Oncology
Patricia Rich, R. Brian Mitchell, Eric Schaefer, Paul R. Walker, John W. Dubay, Jason Boyd, David Oubre, Ray Page, Mazen Khalil, Suman Sinha, Scott Boniol, Hafez Halawani, Edgardo S. Santos, Warren Brenner, James M. Orsini, Emily Pauli, Jonathan Goldberg, Andrea Veatch, Mitchell Haut, Bassam Ghabach, Savita Bidyasar, Maria Quejada, Waseemullah Khan, Kan Huang, Linda Traylor, Wallace Akerley
Summary: Blood-based HIC proteomic testing provides clinically meaningful information for immunotherapy treatment decision in NSCLC independent of PD-L1 levels. Results showed that HIC-H patients had longer overall survival compared to HIC-C patients across different treatment regimens, recommending against using ICI therapy alone for HIC-C patients regardless of their PD-L1 expression.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Jie Zhao, Yayi He, Xue Yang, Panwen Tian, Liang Zeng, Kun Huang, Jing Zhao, Jiaqi Zhou, Yin Zhu, Qiyuan Wang, Mailin Chen, Wen Li, Yi Gao, Yongchang Zhang, Yang Xia
Summary: This retrospective study investigated the treatment outcomes of patients with extensive-stage small cell lung cancer (ES-SCLC) receiving chemoimmunotherapy. The study found that a clinical and radiomics model could predict the treatment outcomes in these patients.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Biagio Ricciuti, Greg Jones, Mariano Severgnini, Joao Alessi, Gonzalo Recondo, Marissa Lawrence, Tim Forshew, Christine Lydon, Mizuki Nishino, Michael Cheng, Mark Awad
Summary: In patients with advanced NSCLC, changes in ctDNA levels after pembrolizumab treatment may predict treatment response before radiological assessment. Early decreases in ctDNA corresponded with clinical benefit, suggesting a potential role for ctDNA as an early pharmacodynamic biomarker of response or resistance to immunotherapies.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
D. R. Spigel, D. Vicente, T. E. Ciuleanu, S. Gettinger, S. Peters, L. Horn, C. Audigier-Valette, N. Pardo Aranda, O. Juan-Vidal, Y. Cheng, H. Zhang, M. Shi, A. Luft, J. Wolf, S. Antonia, K. Nakagawa, J. Fairchild, C. Baudelet, D. Pandya, P. Doshi, H. Chang, M. Reck
Summary: Nivolumab did not show survival benefit compared to chemotherapy in relapsed SCLC, but there is a potential survival benefit in certain baseline characteristics.
ANNALS OF ONCOLOGY
(2021)
Article
Oncology
Chester Kao, Eric Powers, Yuan Wu, Michael B. Datto, Michelle F. Green, John H. Strickler, Neal E. Ready, Tian Zhang, Jeffrey M. Clarke
Summary: In this study of 88 NSCLC patients, tumor mutational burden (TMB), PD-L1, and NLR were found to be modest biomarkers for response to immune checkpoint inhibitors. TMB was the strongest predictor, but combining all three biomarkers improved the prediction of treatment response.
CLINICAL LUNG CANCER
(2021)
Article
Physics, Applied
Abraham Lin, Eline Biscop, Yury Gorbanev, Evelien Smits, Annemie Bogaerts
Summary: This study investigated the energy dependence of a pulsed-dielectric barrier discharge plasma treatment on chemical species production and biological responses. The results suggest that the delivered plasma energy plays a predominant role in stimulating a biological response in vitro, aiding in developing steps toward defining a plasma treatment unit and treatment dose for biomedical and clinical research.
PLASMA PROCESSES AND POLYMERS
(2022)
Article
Biology
George Elias, Pieter Meysman, Esther Bartholomeus, Nicolas De Neuter, Nina Keersmaekers, Arvid Suls, Hilde Jansens, Aisha Souquette, Hans De Reu, Marie-Paule Emonds, Evelien Smits, Eva Lion, Paul G. Thomas, Geert Mortier, Pierre Van Damme, Philippe Beutels, Kris Laukens, Viggo Van Tendeloo, Benson Ogunjimi
Summary: This study demonstrates the significant impact of preexisting memory CD4 T cell clones on vaccine-induced immunity to hepatitis B. The presence of these clones can predict the strength and timing of the immune response to vaccination.
Article
Chemistry, Applied
Alastair B. Ross, Evelyne Maes, Erin J. Lee, Ines Homewood, Jennifer M. Marsh, Stephanie L. Davis, Robert J. Willicut
Summary: This study used lipidomics to investigate the impact of UV light on hair lipids. The results showed that UV exposure decreased several lipid classes and increased others.
INTERNATIONAL JOURNAL OF COSMETIC SCIENCE
(2022)
Article
Oncology
Yana Debie, Jonas R. M. Van Audenaerde, Timon Vandamme, Lieselot Croes, Laure-Anne Teuwen, Lise Verbruggen, Greetje Vanhoutte, Elly Marcq, Lisa Verheggen, Debbie Le Blon, Bart Peeters, Maria E. Goossens, Pieter Pannus, Kevin K. Arien, Sebastien Anguille, Annelies Janssens, Hans Prenen, Evelien L. J. Smits, Christof Vulsteke, Eva Lion, Marc Peeters, Peter A. van Dam
Summary: Patients with cancer have reduced humoral responses after double-dose COVID-19 vaccination, but their cellular response is comparable to healthy individuals. A third dose of BNT162b2 can boost immune responses in both healthy people and cancer patients. This study compares the effects of a third dose of BNT162b2 after homologous (double-dose BNT162b2) and heterologous (ChAdOx1) vaccination in cancer patients.
CLINICAL CANCER RESEARCH
(2023)
Article
Pathology
Ximena Baez-Navarro, Mieke R. van Bockstal, Dienna Nawawi, Glenn Broeckx, Cecile Colpaert, Shusma C. Doebar, Marieke C. H. Hogenes, Esther Koop, Kathleen Lambein, Dieter J. E. Peeters, Renata H. J. A. Sinke, Johannes Bastiaan van Brakel, Jose van der Starre-Gaal, Bert van der Vegt, Koen van de Vijver, Celien P. H. Vreuls, Willem Vreuls, Pieter J. Westenend, Carolien H. M. van Deurzen
Summary: A multicenter international study assessed the interobserver agreement in specific HER2 immunohistochemistry scores for breast cancer. The current guidelines may not be sufficient for identifying HER2-low tumors. Modifying the scoring criteria or adding fluorescent in situ hybridization may improve the agreement.
Article
Oncology
Christophe Deben, Edgar Cardenas de la Hoz, Maxim Le Compte, Paul Van Schil, Jeroen M. H. Hendriks, Patrick Lauwers, Suresh Krishan Yogeswaran, Filip Lardon, Patrick Pauwels, Steven Van Laere, Annemie Bogaerts, Evelien Smits, Steve Vanlanduit, Abraham Lin
Summary: A high-throughput and automated live-cell image analysis software called OrBITS was developed for kinetic monitoring of organoids. The software combines computer vision with convolutional network machine learning and was validated against standard assays. Using OrBITS, the drug screening of lung and pancreatic cancer treatments provided further insights into the drugs' mechanism of action.
Review
Pharmacology & Pharmacy
Abraham Lin, Maxime Sahun, Eline Biscop, Hanne Verswyvel, Jorrit De Waele, Joey De Backer, Claudia Theys, Bart Cuypers, Kris Laukens, Wim Vanden Berghe, Evelien Smits, Annemie Bogaerts
Summary: This study aimed to investigate the mechanisms of NTP therapy sensitivity and resistance by using the first-ever NTP-resistant cell line derived from sensitive melanoma cells. The cells were exposed to NTP for 12 weeks and evaluated against the parental control cells. Transcriptome sequencing and metabolic analysis revealed a preference towards aerobic glycolysis and increased vulnerability to lipid peroxidation and ferroptosis in NTP-resistant cells.
DRUG RESISTANCE UPDATES
(2023)
Article
Oncology
Tal Flieswasser, Astrid van den Eynde, Laurie Freire Boullosa, Joeran Melis, Christophe Hermans, Celine Merlin, Ho Wa Lau, Jonas Van Audenaerde, Filip Lardon, Evelien Smits, Patrick Pauwels, Julie Jacobs
Summary: In this study, the cytotoxic and immune stimulatory potential of an anti-CD70 therapy in NSCLC was explored. The results showed that anti-CD70 therapy resulted in NK-mediated killing of NSCLC cells and increased production of pro-inflammatory cytokines by NK cells. Combination of chemotherapy and anti-CD70 therapy further enhanced NSCLC cell killing and improved survival in vivo.
Article
Biochemistry & Molecular Biology
Laurie Freire Boullosa, Jinthe Van Loenhout, Tal Flieswasser, Christophe Hermans, Celine Merlin, Ho Wa Lau, Elly Marcq, Marlies Verschuuren, Winnok H. De Vos, Filip Lardon, Evelien L. J. Smits, Christophe Deben
Summary: The study aims to enhance the efficacy of auranofin (AF) as a cancer treatment by combining it with the PARP inhibitor olaparib (referred to as 'aurola'). High concentrations of AF and olaparib synergistically induced cytotoxicity in NSCLC and PDAC cell lines with low levels of mutant p53 protein. The combination strategy of oxidative stress induction with PARP inhibition could be a promising treatment for mutant p53 cancers.
Review
Oncology
Jeppe Thagaard, Glenn Broeckx, David B. Page, Chowdhury Arif Jahangir, Sara Verbandt, Zuzana Kos, Rajarsi Gupta, Reena Khiroya, Khalid Abduljabbar, Gabriela Acosta Haab, Balazs Acs, Guray Akturk, Jonas S. Almeida, Isabel Alvarado-Cabrero, Mohamed Amgad, Farid Azmoudeh-Ardalan, Sunil Badve, Nurkhairul Bariyah Baharun, Eva Balslev, Enrique R. Bellolio, Vydehi Bheemaraju, Kim R. M. Blenman, Luciana Botinelly Mendonca Fujimoto, Najat Bouchmaa, Octavio Burgues, Alexandros Chardas, Maggie U. Cheang, Francesco Ciompi, Lee A. D. Cooper, An Coosemans, German Corredor, Anders B. Dahl, Flavio Luis Dantas Portela, Frederik Deman, Sandra Demaria, Johan Dore Hansen, Sarah N. Dudgeon, Thomas Ebstrup, Mahmoud Elghazawy, Claudio Fernandez-Martin, Stephen B. Fox, William M. Gallagher, Jennifer M. Giltnane, Sacha Gnjatic, Paula Gonzalez-Ericsson, Anita Grigoriadis, Niels Halama, Matthew G. Hanna, Aparna Harbhajanka, Steven N. Hart, Johan Hartman, Soren Hauberg, Stephen Hewitt, Akira Hida, Hugo M. Horlings, Zaheed Husain, Evangelos Hytopoulos, Sheeba Irshad, Emiel A. M. Janssen, Mohamed Kahila, Tatsuki R. Kataoka, Kosuke Kawaguchi, Durga Kharidehal, Andrey Khramtsov, Umay Kiraz, Pawan Kirtani, Liudmila L. Kodach, Konstanty Korski, Aniko Kovacs, Anne-Vibeke Laenkholm, Corinna Lang-Schwarz, Denis Larsimont, Jochen K. Lennerz, Marvin Lerousseau, Xiaoxian Li, Amy Ly, Anant Madabhushi, Sai K. Maley, Vidya Manur Narasimhamurthy, Douglas K. Marks, Elizabeth S. McDonald, Ravi Mehrotra, Stefan Michiels, Fayyaz ul Amir Afsar Minhas, Shachi Mittal, David A. Moore, Shamim Mushtaq, Hussain Nighat, Thomas Papathomas, Frederique Penault-Llorca, Rashindrie D. Perera, Christopher J. Pinard, Juan Carlos Pinto-Cardenas, Giancarlo Pruneri, Lajos Pusztai, Arman Rahman, Nasir Mahmood Rajpoot, Bernardo Leon Rapoport, Tilman T. Rau, Jorge S. Reis-Filho, Joana M. Ribeiro, David Rimm, Anne Roslind, Anne Vincent-Salomon, Manuel Salto-Tellez, Joel Saltz, Shahin Sayed, Ely Scott, Kalliopi P. Siziopikou, Christos Sotiriou, Albrecht Stenzinger, Maher A. Sughayer, Daniel Sur, Susan Fineberg, Fraser Symmans, Sunao Tanaka, Timothy Taxter, Sabine Tejpar, Jonas Teuwen, E. Aubrey Thompson, Trine Tramm, William T. Tran, Jeroen van Der Laak, Paul J. van Diest, Gregory E. Verghese, Giuseppe Viale, Michael Vieth, Noorul Wahab, Thomas Walter, Yannick Waumans, Hannah Y. Wen, Wentao Yang, Yinyin Yuan, Reena Md Zin, Sylvia Adams, John Bartlett, Sibylle Loibl, Carsten Denkert, Peter Savas, Sherene Loi, Roberto Salgado, Elisabeth Specht Stovgaard
Summary: The clinical significance of tumor-immune interaction in breast cancer has been established. Tumor-infiltrating lymphocytes (TILs) have emerged as predictive and prognostic biomarkers for patients with triple-negative and HER2-positive breast cancer. The use of machine learning (ML) to automatically evaluate TILs has shown promising results. However, there are challenges in implementing this in trial and routine clinical management, including technical slide issues, ML and image analysis aspects, data challenges, and validation issues.
JOURNAL OF PATHOLOGY
(2023)
Article
Oncology
Gizem Oner, Glenn Broeckx, Christophe Van Berckelaer, Karen Zwaenepoel, Sevilay Altintas, Zafer Canturk, Wiebren Tjalma, Zwi Berneman, Marc Peeters, Patrick Pauwels, Peter A. van Dam
Summary: This study aims to investigate the tumor microenvironment and immune response in ER+/HER-2 negative breast cancer during neoadjuvant endocrine therapy (NET), and correlate this with treatment response. The results show that NET can influence the composition and functional state of infiltrating immune cells, and is associated with treatment response.
Review
Oncology
Omar Najim, Konstantinos Papadimitriou, Glenn Broeckx, Manon Huizing, Wiebren Tjalma
Summary: This meta-analysis aimed to compare the prevalence of ESR1 mutation detected with liquid biopsy and tissue biopsy. The findings suggest that liquid biopsy is a valid, inexpensive, and attractive noninvasive alternative to tumor biopsies for the identification of ESR1 mutations.
FRONTIERS IN ONCOLOGY
(2023)
Article
Biology
Kerlijne Moorkens, Jo L. M. R. Leroy, Jusal Quanico, Geert Baggerman, Waleed F. A. Marei
Summary: This study investigated the changes in lipid metabolism in the oviduct of mice fed an obesogenic diet. The results showed that the obesogenic diet led to an increase in the overall lipid levels and differential regulation of specific lipids in the oviductal epithelium. These lipidomic changes may impact reproductive events in the oviduct, such as fertilization and early embryo development.
Meeting Abstract
Oncology
Gizem Oner, Glenn Broeckx, Christophe Van Berckelaer, Sevilay Altintas, Zafer Canturk, Wiebren Tjalma, Karen Zwaenepoel, Zwi Berneman, Marc Peeters, Patrick Pauwels, Peter A. van Dam